This research is being done to find out whether subjects previously treated with the implantable insulin pump (IIP) therapy, and now taking insulin by injection, will benefit from re-implantation of IIP. We will see if IIP causes more stable control of blood sugar, with fewer highs and lows. People with type 1 diabetes previously implanted with the MiniMed Implantable Pump (MIP) model 2000 at Johns Hopkins may join this study.

If you join the study and choose to have a new pump implanted, the study is expected to last 12-15 months for each person, and you will continue to be followed, with 3-monthly refills and research visits for as long as the pump lasts, until you choose to withdraw, until the FDA approves the pump for regular care, or until the company stops supporting the pump. During the first 12-15 months of the study, there will be an estimated 13 clinic visits and one hospital stay for 2-3 days. The data collection visits will take about 30 minutes, and a continuous glucose monitor will be started. You will have a brief visit 3-4 days later to drop off the monitor. After this phase of the research, you will still be cared for with the implanted pump, having visits for refills and tests every 3 months. This long-term follow up will last until you choose to withdraw, the pump malfunctions, the FDA approves the pump for regular care, or the company no longer supports the pump. If you are no longer taking part in the study, we will have the pump removed from your body.

Eligibility

Genders Eligible for Study:

Both

Criteria

Inclusion Criteria:

People with type 1 diabetes previously implanted with the MiniMed Implantable Pump model 2000 at Johns Hopkins may join this study.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00298740